Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:LMNL

Liminal BioSciences (LMNL) Stock Price, News & Analysis

Liminal BioSciences logo

About Liminal BioSciences Stock (NASDAQ:LMNL)

Key Stats

Today's Range
$8.48
$8.50
50-Day Range
$8.38
$8.50
52-Week Range
$3.10
$8.50
Volume
5,000 shs
Average Volume
63,470 shs
Market Capitalization
$26.35 million
P/E Ratio
29.31
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Receive LMNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liminal BioSciences and its competitors with MarketBeat's FREE daily newsletter.

LMNL Stock News Headlines

JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
See More Headlines

LMNL Stock Analysis - Frequently Asked Questions

Liminal BioSciences Inc. (NASDAQ:LMNL) announced its quarterly earnings data on Monday, November, 15th. The company reported $27.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.80) by $30.20. The firm had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.02 million. Liminal BioSciences had a net margin of 248.35% and a negative trailing twelve-month return on equity of 88.44%.

Liminal BioSciences shares reverse split on Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Liminal BioSciences investors own include Corbus Pharmaceuticals (CRBP), Bionano Genomics (BNGO), HubSpot (HUBS), iBio (IBIO), Dynavax Technologies (DVAX), Diamondback Energy (FANG) and NIO (NIO).

Company Calendar

Last Earnings
11/15/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LMNL
Employees
251
Year Founded
N/A

Profitability

Net Income
$380,000.00
Pretax Margin
-5,729.40%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$8.97 per share

Miscellaneous

Free Float
3,036,000
Market Cap
$26.35 million
Optionable
Not Optionable
Beta
1.03
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:LMNL) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners